- "Bezisterim" has been approved as the non-proprietary name for NE3107
- Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation
CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston, Massachusetts April 23-25.
The presentationClinical...
Login or create a forever free account to read this news
Sign up/Log in